Kornimate/medical-research-clean huggingface dataset:
mod&jeu: moderators of online gambling, how effective?

Conditions: Online Gambling

Summary: prevalence of problem gambling is estimated about 1-3% of the general adult population. this percentage increases to 5% when talking about online gambling. in france, the market for online gambling was recently opened up to competition and regulation (may 2010), including poker and sports/horse races betting, but excluding for the moment casino games. recent international studies show that legalizing online gambling led to an increase of practices, including problem gambling. in france, the law stipulates the establishment of moderators of online gambling, to prevent excessive gambling practices. the regulatory authority of online games (arjel) guarantees the implementation of these moderators. however, no evaluation of the effectiveness of these moderators is planned. therefore the investigators propose to conduct an experimental study about online gambling. the objective will be to evaluate the effectiveness of four kinds of moderators, some already legislated, but not evaluated, and others offered by the investigators team. proposals for amending legislation will be made according the results of this study.


Eligibility criteria:
inclusion criteria: * adult * french people, living around nantes * giving their consent for access to their gambling account * user of a gambling site approved by the arjel, with an active account * regular gambler (gambling at least once a week, since at least 3 months) exclusion criteria: * age under 18 and over 65 * excessive gamblers (cpgi \> 8) or gambler seeking treatment * protected persons (pregnant women, being under protection measures) * overindebtedness * psychiatric or cognitive major dysfunctions

Keywords: experimental study, moderators, online gambling, problem gambling prevention
rapamycin treatment for activated phosphoinositide 3-kinase δ syndrome

Conditions: Activated PI3K-delta Syndrome; Immunodeficiency Primary

Summary: the purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (apds).

activated phosphoinositide 3-kinase δ syndrome (apds) is a recently described autosomal dominant primary immunodeficiency (pid), caused by the mutations in pik3cd gene. the manifestations of apds mainly include recurrent respiratory tract infections, persistent epstein-barr virus (ebv)/ cytomegalovirus (cmv)infections, lymphadenopathy, splenomegaly, cd4+t cells lymphopenia, and hyper-igm syndrome. pik3cd encodes p110δ, the catalytic subunit of phosphatidylinositol 3-kinase (pi3k) which mainly expresses in leukocytes, being critical for their proliferation, activation and survival. gain-of-function (gof) pik3cd mutations lead to pi3kδ hyperactivity, with the downstream mediators akt and mammilian target of rapamycin (mtor) hyperphosphorylated. patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated akt protein. hyperactivation of mtor increases phosphorylation of kinases and increased glycolysis that results in enhanced proliferation and senescence of terminally differentiated cd8+ tcell populations. the optimal treatment for these apds patients is not yet determined; however, there are many kinds of therapeutic approaches (anti-infection prophylaxis, immunoglobulin replacement, conventional immunosuppressants, pi3k/mtor inhibitors and hematopoietic stem cell transplantation). the apds patients frequently receive treatment with immunoglobulin replacement and antibiotics. hematopoietic stem cell transplantation (hsct) has been currently curative in apds patients; however, longer-term follow-up to determine the degree of donor chimerism and efficacy is required. there are several subjects without a prompt suitable matched donor or for whom the critical disease conditions force to postpone hsct.the mammalian/mechanistic target of inhibitor rapamycin was reported to improve circulating t-cell profiles. individual patients in previous studies experienced a decrease in nonneoplastic lymphoproliferation while taking rapamycin. the investigators in this study hope to evaluate the efficacy and safety of rapamycin in the treatment for carefully selected patients with apds.

Eligibility criteria:
inclusion criteria: 1. patients with activated phosphoinositide 3-kinase δ syndrome 2. no more than 18 years old exclusion criteria: 1. patients with serious fungous infection 2. patients with serious complications 3. lack of parental consent

Keywords: activated pi3k-delta syndrome immunodeficiency primary akt/mtor pathway rapamycin therapy hyperphosphorylation
effect of plant sterols esterified to fish oil fatty acids on plasma lipid levels

Conditions: Dyslipidemia

Summary: the purpose of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly ldl-cholesterol and tg concentrations in healthy hyperlipidemic subjects.

phytosterols and omega-3 fatty acids (n-3) are natural food ingredients with potential cardiovascular (cvd) benefits. phytosterols inhibit dietary cholesterol absorption and biliary cholesterol re-absorption, thereby reducing blood cholesterol levels, while consumption of n-3 is associated with a significant reduction in plasma triglyceride concentrations. furthermore, n-3 may also beneficially modify a number of other risk factors of chd, like anti-inflammatory and anti-thrombotic. the primary objective of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly ldl-cholesterol and tg concentrations in healthy hyperlipidemic subjects. in addition the supplement efficacy to lower other cvd-related risk factors of healthy will be evaluated.

Eligibility criteria:
inclusion criteria: * male or female, \>18 years old and ≤ 70 years old, capable and willing to give written informed consent. * subject must have hyperlipidemia at the screening visit and at the end of the run-in period, defined as: fasting plasma triglycerides \> 150 mg/dl and \ 130 mg/dl and \< 190 mg/dl. * fasting plasma glucose (fpg) levels at the screening visit \< 110 mg/dl. * female patient who is of reproductive potential agree to use acceptable methods of birth control * female patient who is currently receiving hormone replacement therapy continuously 12 weeks before visit 1 (on stable dose) and will agree to do so during the study. exclusion criteria: * receiving medications or supplements known to affect lipid metabolism. * uncontrolled hypertension or thyroid disease. * consume unusual diets - will be determined at the discretion of the investigator. * gained or lost more than 3 kg during the run-in period. * patient has history of malignancy ≤ 5 years. * patients with clinical ischemic cv disease on treatment * consume 200 grams fish x 2 a week. * gastrointestinal disease or any disease that the investigator feels would compromise the patient safety or limit his/her successful participation to the study. * patient has type 1 or type 2 diabetes mellitus. * patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins * patient has had active peptic ulcer disease within 3 months of visit 1. * woman patient is pregnant or breast-feeding or expecting to conceive during the study. * patient has a history of hypersensitivity or allergy to fish, fish oil, corn oil or soy.

Keywords: hypercholesterolemia hypertriglyceridemia plant sterol cholesterol fish oil
magnetic resonance imaging to predict outcomes in aortic aneurysms

Conditions: Abdominal Aortic Aneurysm

Summary: the aorta is the main blood vessel that comes out of the heart and distributes blood to the whole body. in some people, the aorta becomes swollen (aneurysm) and bursts, especially as it passes through the abdomen. these 'abdominal aortic aneurysms' often occur without symptoms and can burst or rupture without warning. this usually leads to death and represents the thirteenth commonest cause of death in the united kingdom. in this study, we are looking at a new technique that can look at the aortic aneurysm using magnetic resonance imaging; a technique that does not require x-rays or radiation. we have recently shown that, using magnetic resonance combined with a new imaging agent uspio, we can detect 'hotspots' of activity in these aneurysms that seem to predict which aneurysms grow rapidly, and are therefore potentially at risk of rupture. we here propose to conduct a study in edinburgh that will invite all patients who are under surveillance because of an aneurysm. we will image these patients using this novel technique and see if we can identify which patients burst their aneurysm, have an aneurysm that grows so large it needs to have surgery, or die. this will be important to establish as it will potentially lead to a new way of managing people that could ultimately save lives. this is particularly timely as national screening and surveillance programmes are currently being launched.

hypothesis we hypothesise that uptake of ultrasmall supraparamagnetic particles of iron oxide into the aortic wall will predict abdominal aortic aneurysm growth and clinical outcomes.

Eligibility criteria:
inclusion criteria: patients with an abdominal aortic aneurysm \>40 mm exclusion criteria: 1. any medical history or clinically relevant abnormality identified on the screening medical examination, vital sign measurement, or clinical laboratory examination that is deemed by the principal investigator and/or designee to make the subject ineligible for inclusion. 2. subjects with planned aaa surgery. 3. renal impairment with egfr of \<30 mls/min at screening, history of kidney transplant or history of contrast nephropathy. 4. women of child-bearing potential without contraception, 5. collagen-vascular disease. 6. inability to undergo magnetic resonance or computed tomography scanning, 7. contraindication to mri scanning (as assessed by local mri safety questionnaire) which includes but not limited to: * intracranial aneurysm clips (except sugita) or other metallic objects, * history of intra- orbital metal fragments that have not been removed, * pacemakers, implantable cardiac defibrillators and non-mr compatible heart valves, * inner ear implants, * history of claustrophobia in mr.

Keywords: abdominal aortic aneurysm mri uspio
efficacy and safety study of desloratadine (mk-4117) in japanese participants with eczema/dermatitis and dermal pruritus (mk-4117-202)

Conditions: Eczema; Dermatitis; Dermal Pruritus

Summary: this is an efficacy and safety study of up to 12 weeks of desloratadine in japanese participants with eczema/dermatitis and dermal pruritus. the primary hypothesis of this study is that the sum of the daytime and nighttime pruritus/itch scores for both the eczema/dermatitis group and the dermal pruritus group will be significantly improved at week 2 compared to baseline.


Eligibility criteria:
inclusion criteria: * eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema, neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus is appropriate) * dermal pruritus (generalized dermal pruritus, localized dermal pruritus) exclusion criteria: * hypersensitivity to antihistamines or ingredients of a study drug

Keywords: dermatitis dermatitis, atopic skin diseases skin diseases, genetic genetic diseases, inborn skin diseases, eczematous hypersensitivity, immediate hypersensitivity immune system diseases
constraint-induced movement therapy versus cross education in children with cerebral palsy

Conditions: Hemiplegic Cerebral Palsy

Summary: this clinical trial aims to compare the effectiveness of lower limb cimt and the strength training of the non-hemiplegic lower limb on motor performance in hemiplegic children with cp. participants will: diagnosed with hemiplegic cerebral palsy treated with cimt or strength training (cross-education) for a non-hemiplegic limb for 8 weeks. 3 sessions per week. measurements will be taken at baseline and then at the end of the 8 weeks.

method: 32 children with hemiplegic cp will be equally and randomly allocated to two groups (group a and b). group a will receive lower limb cimt for the non- hemiplegic limb using whole leg orthosis and group b will receive strengthen training for the non-hemiplegic lower limb. both groups will receive routine physical therapy for the hemiplegic lower limb. both groups will receive 60 minutes training session for 3 sessions per week for 8 consecutive weeks. assessment will be at baseline then at the end of trial.

Eligibility criteria:
inclusion criteria: 1. children with hemiplegic cerebral palsy aged age between 4 and 10. 2. (gmfcs) levels i, ii and iii. 3. able to follow therapist instructions during training session. exclusion criteria: 1. lack of patient's cooperation. 2. difficulty wearing constraint method due to severe joint deformation or/and contracture. 3. patients were treated with botulinum toxin during the last 3 months. 4. seizure disorder not fully controlled by medication.
high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius

Conditions: Neck Pain

Summary: to investigate the effect of high intensity laser versus ischemic compression on myofascial trigger points on neck pain, cervical range of motion,pressure pain thershold and cervical disability and to show that the more effectivness therapy will provide significant clinical value

randomized controlled trial , participants will be assigned into three groups (study group a ,study group b and study group c ) subject selection will be 63 subjects , 21 subjects in each group with trigger points in the upper trapezius. groups

Eligibility criteria:
inclusion criteria: * the age of patients range from 20 to 50 years . * patient body mass index starting from 19 to 25 kg\\m. * presence of myofascial trigger points in the shortened upper trapezius muscle evaluated . exclusion criteria: * patients with fibromyalgia syndrome. * cancer or tumor or any type diagnosed . * patients with disc herniation or spinal canal stenosis. * pregnancy - * patients diagnosed with epilepsy.

Keywords: "myofascial pain syndrome" "trigger points" "high intensity laser " "ischemic compression"
school-age children with autism with limited expressive language skills

Conditions: Autism Spectrum Disorder

Summary: this project will address a major challenge to the field of autism research: improving expressive communication in children with autism who have reached school age but have not acquired functional spoken language (non-verbal school aged children with autism; nvsaca). fifteen children who completed the ro1 ican intervention (nct01018407) at the kennedy krieger site and follow-up testing but continue to have minimal functional spoken language will be participants in this study. after eligibility is established, participants will be randomly assigned to a baseline duration of one week, two weeks or three weeks before the start of active treatment. once the baseline duration is completed, participants begin active treatment one hour of intervention three days per week in the participants' school setting. in month 2, weekly teacher trainings begin. in month 5, weekly parent trainings begin to improve the child's generalization of skills and teach parents the strategies implemented in their child's treatment. post-baseline and post-treatment assessments will be completed in the lab at a time that is convenient for the participants' families.


Eligibility criteria:
inclusion criteria: * diagnosis of autism by a licensed psychologist or board certified developmental pediatrician, or child and adolescent psychiatrist, confirmed by the autism diagnostic observation schedule (ados; lord, rutter, dilavore, \& risi, 1999) * chronological age between 4.0 years and 7 years, 11 months * reynell developmental score ≤ 24 months, ados a1 score of 2, 3 or 8 * nonverbal iq of ≥ 40 (leiter international performance scale-revised (leiter-r), roid \& miller, 2007) * children have participated in and completed follow-up testing for the ican study. exclusion criteria: * major medical conditions other than autism (e.g., genetic disorders \[e.g., fragile x, down syndrome, tuberous sclerosis\], blindness or deafness, and motor disabilities such as cerebral palsy; * uncontrolled seizures; * self-injurious behavior or moderate to severe aggression. * children in foster care. * children who are exposed to \< 50% english throughout their typical day. * children currently participating in another intervention/treatment study.

Keywords: autism spectrum disorder language intervention school-age
how to reduce suicidal thoughts and impulsivity in depression

Conditions: Unipolar Depression; Impulsive Behavior; Suicidal Ideation

Summary: the study aims at investigating if tdcs applied to left dlpfc or to right ofc to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode.

depressive disorders are one of the most frequent pathologies in psychiatry. the lifetime prevalence of the characterized depressive episode is indeed particularly high, between 16.6% in the united states and 24.1% in france. because of this high prevalence, and because they constitute a pathology with a high risk of suicidal behavior (sc), depressive disorders are a major target of medical strategies for suicide prevention. in addition to suicidal ideation, impulsivity, considered as the tendency to express spontaneous, excessive and/or unplanned behaviors, is recognized as being a major factor precipitating scs. with a pilot, prospective, multicenter design, the perspectives of depimpulse include being able to develop an innovative therapeutic approach in the reduction of risky behaviors, in particular suicidal ideation, associated impulsivity, suicidal risk in patients suffering from depression, while improving our understanding of the behavioral aspects and associated cognitions. the treatment will be delivered during 5 consecutive days (d1 to d5). baseline measures (d0) will be compared to those obtained after the treatment administration (last day of treatment (d5) and 2 weeks (+w2) and 1 month (+w4) after the end of treatment.

Eligibility criteria:
inclusion criteria: * man or woman older than 18 years oldright-handed * signed informed consent form * subject affiliated to or beneficiary from a french social security regime * inpatient or outpatient at the adult psychiatry service * diagnosis of major depressive disorder according to the 5th edition of diagnostic and statistical manual of mental disorders (dsm-5) criteria and confirmation by the mini structured clinical interview * madrs score ≥ 18 * beck scale for suicide ideation (bss) score ≥8 * under antidepressant treatment * absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases) exclusion criteria: * tdcs contraindication * younger than 18 years old * left-handed * under mood stabilizer and/or antiepileptic * treated by ect or rtms or tdcs for the current eposide * subject under measure of protection or guardianship of justice * presence of other psychiatric pahtologies * subject beneficiary from a legal protection regime * subject unlikely to cooperate or low cooperation stated by investigator * subject not covered by social security * pregnant woman * subject being in the exclusion period of another study or provided for by the "national volunteer file"

Keywords: transcranial stimulation tdcs left prefrontaldorsolateral cortex right orbitofrontal cortex
the glucopred investigation ii

Conditions: Diabetes Mellitus, Type 1

Summary: diabetes mellitus type 1 (dm1) is an autoimmune metabolic disease in which the insulin producing cells in the pancreas are destroyed and the subject is left totally dependent of external supply of insulin. there is no known cure for dm1 except for in very specific situations. thus, management of dm1 concentrates on keeping blood glucose levels as close to normal levels. as an aid to subjects with dm1 for managing their blood glucose levels as close to normal as possible, blood glucose monitoring systems have been developed. available blood glucose monitoring systems today require a capillary blood sample that is analysed by a glucose meter. subjects are normally advised by health care professionals on the appropriate blood glucose monitoring regime for their condition. however, many subjects fail to measure blood glucose as often as needed to achieve good blood glucose control despite every effort from health care professionals. research and development of non-invasive interstitial blood glucose monitoring methods is ongoing. all attempts to develop a non-invasive continuous glucose measuring device have so far failed. prediktor medical as has developed a non-invasive sensor, glucopred, based on the combination of several non-invasive measurement principles and multivariate analysis and dynamic models of glucose/insulin interaction. the device will be body mounted in the form of a bracelet or a watch communicating with a mobile phone or a tablet for data presentation and collection. development of glucopred is now at a stage where testing of the sensor in subjects under controlled settings is required before further development can take place. if successful, this will be a major step ahead for all patients with diabetes and markedly increase their possibility to take care of their disease on a day to day basis without the burden of frequent blood sampling or wearing an invasive device.


Eligibility criteria:
inclusion criteria: * diabetes mellitus type 1 * has read and understood the informed consent documentation and is willing to participate in the investigation and willing to sign the informed consent form * willing to participate in the investigation using one or two glucopred sensors for a period of 8 days * willing to attend 2 investigational visits with duration of up to 4 hours during the investigational period * willing to take and record up to 16 finger-stick blood samples on day 1 and up to 8 finger-stick blood samples daily for measuring reference values for the duration of the investigation * uses a blood-glucose monitoring system for self-testing on a daily basis * willing to use the provided blood-glucose monitoring system during the investigation * has access to and is willing to use a computer for downloading data and charging the sensor exclusion criteria: * not fit for the investigation due concurrent illness * unfit for participation for any reason judged by the investigator * pregnancy

Keywords: blood glucose self-monitoring